Published by Josh White on 27th October 2020
(Sharecast News) - Specialist drug development company Sareum Holdings announced on Tuesday that its application for a grant of around £0.17m from UK Research and Innovation (UKRI) to investigate the therapeutic potential of 'SDC-1801', its selective, small molecule TYK2/JAK1 kinase inhibitor in severe phase Covid-19, had been conditionally approved.